FDA Inspection 1319538 — Rubicon Research Canada Limited
The FDA completed an inspection of Rubicon Research Canada Limited on April 24, 2026 in Concord. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- April 24, 2026
- Fiscal Year
- 2026
- Product Type
- Drugs
- Project Area
- Bioresearch Monitoring
- Location
- Concord (Canada)
Additional Details
Bioanalytical BA/BE